Even minor structural variations in peptide therapeutics can potentially impact efficacy, pharmacokinetics, immunogenicity, and long-term product stability, potentially leading to biosimilar comparability failure if not properly characterized
Of 18 SLE patients on GLP-1 medications, only one experienced a mild-to-moderate flare during follow-up
This is a straightforward reason that, on the systemic route, more is not obviously better and may simply mean more copper exposure without a demonstrated skin payoff another argument for treating injectable skin claims skeptically
Although direct monitoring of fetal blood glucose concentrations immediately post-Sem injection was not performed, the absence of a reduction in the body weights of fetuses from glucose-supplemented dams discounts the notion that the decrease in fetal glucose levels is responsible for the fetal growth restriction induced by maternal GLP-1R activation
Changing the dose for special conditions needs careful thought and a doctors advice
This approach captures both the protective daytime benefits and the regenerative nighttime benefits
